Please login to the form below

Not currently logged in
Email:
Password:

Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

Both EU and US regulatory advisors are currently assessing the drug

Pfizer

Regulatory reviews have started for Pfizer’s non-small cell lung cancer drug dacomitinib on both sides of the Atlantic, four years after a pair of trial failures left its future in doubt.

The EMA and FDA have started the clock ticking on their appraisals for dacomitinib, a pan-EGFR tyrosine kinase inhibitor, for the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR-activating mutations.

Dacomitinib missed its objectives in two phase III trials reported in 2014, but Pfizer stuck with the drug and completed a third late-stage trial - ARCHER 1050 - which published results last September.

The study showed that dacomitinib improved median progression-free survival (PFS) compared to AstraZeneca’s first-generation EGFR inhibitor Iressa (gefitinib) to 14.7 months from 9.2 months, representing a 41% reduction in risk of disease progression or death.

In the US, the FDA has given dacomitinib priority review status, setting up a possible approval in September that would allow Pfizer to start competing for a share of the first-line EGFR-mutated NSCLC market with Iressa and Roche's Tarceva (erlotinib), another first-generation drug, as well as newer agents like Boehringer Ingelheim’s Giotrif (afatinib).

The problem for Pfizer comes in the form of AZ’s new-generation EGFR blocker Tagrisso (osimertinib), which is also under review as a first-line therapy for EGFR-mutated NSCLC after making rapid inroads into the market to become the standard for second-line treatment. That has resulted in a doubling of the drug’s sales to just under $1bn last year, making it AZ’s biggest-selling oncology drug.

There is still some debate about the best order to deliver the drugs, as all EGFR inhibitors eventually succumb to resistance and lose their efficacy over time, although AZ has argued strongly that Tagrisso is the best option to be used upfront. There have also been reports that some oncologists are already using the drug off-label in treatment-naïve patients.

Dacomitinib will nevertheless add to the array of drugs available to treat this form of lung cancer, and Pfizer’s chief development officer for oncology, Mace Rothenberg, says it “remains a challenging disease and new treatment options are needed”.

EGFR mutations are seen in 10-35% of NSCLC tumours, says the company, and NSCLC is the most common form of lung cancer accounting for around 85% of all cases worldwide.

Article by
Phil Taylor

5th April 2018

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...